Significance and innovations
• The recent-most U.S. national survey of outpatient physician visit data shows that 76.8% visits among RA patients are associated with any DMARD use while 31.7% are associated with specifically biological DMARD use.
• Our results indicate that the type of insurance coverage and provider are significant indicators of RA treatment with traditional and biological DMARDs.
• Type of coverage may be a better indicator of DMARD treatment use than patient race/ethnicity and therefore, inadequate coverage may lead to underutilization of any DMARD treatment, especially the expensive biological DMARDs.
Introduction
Rheumatoid arthritis (RA) is a chronic inflammatory condition that affects multiple joints in the body. The manifestations of RA are mainly chronic pain and joint deformity, which may lead to loss of function.
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In an earlier study (1996) (1997) (1998) (1999) (2000) (2001) (2002) (2003) (2004) (2005) (2006) (2007) Therefore, this study aims to provide new information on prevalence of traditional and biological DMARD use using recentmost NAMCS data. We plan to assess the association of type of coverage in addition to previously studied factors such as type of provider and patient race/ethnicity.
Materials and methods

Data source
The National Ambulatory Medical Care Survey (NAMCS) is a publicly available data collected through a national survey designed for information on the utilization and provision of ambulatory care services in hospital emergency and outpatient department visits. The data source is a nationally representative probability sample of office-based physician practices and outpatient settings across the US that uses a multistage cluster strategy to select physicians in hospital and outpatient settings by geographic location and provider specialty.
Study design and population
We studied all the visits recorded in the NAMCS data with a RA diagnosis using the following diagnosis codes-714.0, 714.1, and 714.3. We included adults (≥18 years) who had a record of RA among the first three diagnoses recorded per visit in the database. We pooled the NAMCS data and the emergency department (ED) files for 2005-2014 and the OPD visit files from 2005 to 2011 for a cross-sectional study design to examine the factors associated with DMARD and biological DMARD use.
Dependent variables
We looked at up to eight new or ongoing medications recorded per visit for RA treatment as the dependent variable. These treatments included any DMARD treatment (traditional or biological), NSAIDs, and glucocorticoids. The visits associated with traditional DMARDs, such as methotrexate, hydroxychloroquine, sulfasalazine, and minoclycline and those with biological DMARDs, such as infliximab, etanercept, adalimumab, certolizumab, abatacept, tocilizumab, and tofacitinib, were included. The primary dependent variable in our analysis was any DMARD treatment compared to no treatment or treatment with NSAIDs and/or glucocorticoids only. Any DMARD use included traditional or biological DMARDs and its combination with NSAIDs and glucocorticoids. Additionally, we analyzed the use of biological DMARDs or its combinations compared to no treatment, treatment with traditional DMARDs, and its combinations or NSAIDs and/or glucocorticoids only.
Independent variables
We used the Andersen Behavioral Model to guide the selection of variables that included predisposing (age, gender, and race/ ethnicity), enabling (type of health insurance coverage, type of provider, and geographic region), and need (number of comorbidities).
We categorized the age groups as less than 45 years, between 45 and 59 years, and 60 years and over. We compared the DMARD use among non-Hispanic White, non-Hispanic Black, Hispanic, and others. We considered the following geographical regions in our analysis-Northeast, Midwest, South, and West. We categorized the type of health insurance as private insurance, Medicare, Medicaid, self-pay, and other, while the type of provider as general physician vs. specialist. Further, we 
